title: Ranitidine bismuth citrate-based triple therapy for seven days, with or without further anti-secretory therapy, is highly effective in patients with duodenal ulcer and Helicobacter pylori infection.
abstract: OBJECTIVE
  To compare the efficacy of two protocols for the eradication of Helicobacter pylori infection and the healing of active duodenal ulcer: (i) ranitidine bismuth citrate (RBC) plus two antibiotics for 7 days, and (ii) the same triple therapy followed by 3 weeks of anti-secretory drug treatment.
  
  
  METHODS
  The study comprised 102 patients with active duodenal ulcer and H. pylori infection; the patients were randomized to open treatment with either RBC 400 mg b.d. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 7 days, or the same treatment followed by 3 weeks of RBC 400 mg b.d. alone. Ulcer healing was confirmed by endoscopy. H. pylori eradication was assessed by endoscopy, rapid urease test and histology.
  
  
  RESULTS
  The ulcer healed in 48/50 patients on RBC-based triple therapy alone (96.0%) and in 51/52 patients on triple therapy plus further anti-secretory treatment (98.1%). On an intention-to-treat basis, H. pylori had been successfully eradicated in 42/50 patients on triple therapy (84.0%) and in 44/52 patients on triple therapy plus anti-secretory treatment (84.6%), while by per protocol analysis the H. pylori eradication rates were 91.3% (42/46) and 89.8% (44/49), respectively.
  
  
  CONCLUSIONS
  One-week triple therapy with RBC, amoxycillin and clarithromycin is highly effective in eradicating H. pylori and healing duodenal ulcers, even if not followed by anti-secretory drug treatment.
authors.affiliation: Department of Internal Medicine, University of Pisa, Italy. s.marchi@inte.med.unipi.it
authors.forename: S
authors.initials: S
authors.lastname: Marchi
authors.forename: F
authors.initials: F
authors.lastname: Costa
authors.forename: M
authors.initials: M
authors.lastname: Bellini
authors.forename: C
authors.initials: C
authors.lastname: Belcari
authors.forename: M G
authors.initials: MG
authors.lastname: Mumolo
authors.forename: A
authors.initials: A
authors.lastname: Tornar
authors.forename: R
authors.initials: R
authors.lastname: Spisni
authors.forename: E
authors.initials: E
authors.lastname: Torelli
authors.forename: G
authors.initials: G
authors.lastname: Maltinti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000627:therapeutic use; D000863:Antacids / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D002985:Clinical Protocols; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000382:microbiology; D004384:Duodenoscopy; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*; D011899:Ranitidine / Q000627:therapeutic use*; D013392:Sucralfate / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000863:Antacids; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D009942:Organometallic Compounds; D013392:Sucralfate; D000658:Amoxicillin; D011899:Ranitidine; D017291:Clarithromycin; C002791:bismuth tripotassium dicitrate